Melanoma News and Research

Latest Melanoma News and Research

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

19 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

BeaconEquity.com releases investment report featuring Antigenics

BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

15 Apr 2010

Investment report on MIPI

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

An ophthalmologist at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eyes of children with a rare cancer in an attempt to save their vision and their eyes.

15 Apr 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

13 Apr 2010

Tips for protection against sun damage

It's never too early to start protecting yourself against sun damage, and if you are a teenage girl this message is especially important.

13 Apr 2010

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Implanting blue light-filtering intraocular lenses during cataract surgery helps maintain visual function and may preserve the health of the retina, specifically in disease states such as age-related macular degeneration, according to a comprehensive review published in the May/June 2010 edition of Survey of Ophthalmology.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Bill to stop under 18s using sunbeds passed by the House of Lords

The private member's bill to protect children and teenagers from the dangers of sunbeds was passed today by the House of Lords after Cancer Research UK's campaign.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC.

8 Apr 2010

Melanoma News and Research

Latest Melanoma News and Research

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

FDA approves BioAlliance Pharma's Oravig for OPC

Serametrix announces commercial launch of serum test for measuring serum antibodies

Decoding genomes from 25,000 cancer samples

BeaconEquity.com releases investment report featuring Antigenics

Investment report on MIPI

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Patients with RLS using rotigotine achieve sustained improvements

Ophthalmologist implants radioactive discs in the eyes of children with rare cancer

ICGC: New era of personalised medicine for cancer patients

Delcath's Phase III PHP-mel trial data accepted for presentation at ASCO's 2010 Annual Meeting

Tips for protection against sun damage

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Bill to stop under 18s using sunbeds passed by the House of Lords

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in